The effects of low-dose ketamine and (2R,6R)-Hydroxynorketamine on affective behaviors associated with protracted oxycodone withdrawal
In subjects with opioid use disorder (OUD), affective symptoms persist long after opioid cessation and contribute to poor treatment outcomes. (2R,6R)-Hydroxynorketamine (HNK), a ketamine metabolite, has emerged as promising rapid-acting and long-lasting antidepressants, but its potential to reduce a...
Uloženo v:
| Vydáno v: | Psychopharmacology |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Germany
04.10.2025
|
| Témata: | |
| ISSN: | 0033-3158, 1432-2072, 1432-2072 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | In subjects with opioid use disorder (OUD), affective symptoms persist long after opioid cessation and contribute to poor treatment outcomes. (2R,6R)-Hydroxynorketamine (HNK), a ketamine metabolite, has emerged as promising rapid-acting and long-lasting antidepressants, but its potential to reduce affective symptoms during protracted oxycodone withdrawal and the mechanism of action remain unclear.
The objective of this study is to investigate the effects of (2R,6R)-HNK and ketamine on affective-like behaviors during oxycodone withdrawal and evaluate the underlying mechanism.
Male and female C57BL/6 N mice were injected with saline or escalating dose of oxycodone for eight consecutive days followed by 30 days of protracted withdrawal. On withdrawal day 1 or 29, mice were treated with saline, (2R,6R)-HNK (10 mg/kg), s.c.), or ketamine (10 mg/kg, s.c.) prior to the social interaction, sucrose preference, or tail suspension test on withdrawal day 30. Additionally, to determine if AMPA receptor signaling was necessary for the treatment effect, NBQX (AMPA receptor antagonist) was administered prior to (2R,6R)-HNK or ketamine in a different cohort of mice.
Both (2R,6R)-HNK and ketamine reversed oxycodone-induced deficits to a similar degree in all behavior tests when administered on withdrawal day 1, and pre-treatment with NBQX attenuated this effect in the tail suspension test but not the social interaction or sucrose preference tests. When ketamine or (2R,6R)-HNK was administered on withdrawal day 29, both treatments alleviated deficits in the tail suspension test but lacked effects in other behaviors.
These findings demonstrate the therapeutic potential of (2R,6R)-HNK and ketamine in alleviating affective symptoms of oxycodone withdrawal. |
|---|---|
| AbstractList | In subjects with opioid use disorder (OUD), affective symptoms persist long after opioid cessation and contribute to poor treatment outcomes. (2R,6R)-Hydroxynorketamine (HNK), a ketamine metabolite, has emerged as promising rapid-acting and long-lasting antidepressants, but its potential to reduce affective symptoms during protracted oxycodone withdrawal and the mechanism of action remain unclear.
The objective of this study is to investigate the effects of (2R,6R)-HNK and ketamine on affective-like behaviors during oxycodone withdrawal and evaluate the underlying mechanism.
Male and female C57BL/6 N mice were injected with saline or escalating dose of oxycodone for eight consecutive days followed by 30 days of protracted withdrawal. On withdrawal day 1 or 29, mice were treated with saline, (2R,6R)-HNK (10 mg/kg), s.c.), or ketamine (10 mg/kg, s.c.) prior to the social interaction, sucrose preference, or tail suspension test on withdrawal day 30. Additionally, to determine if AMPA receptor signaling was necessary for the treatment effect, NBQX (AMPA receptor antagonist) was administered prior to (2R,6R)-HNK or ketamine in a different cohort of mice.
Both (2R,6R)-HNK and ketamine reversed oxycodone-induced deficits to a similar degree in all behavior tests when administered on withdrawal day 1, and pre-treatment with NBQX attenuated this effect in the tail suspension test but not the social interaction or sucrose preference tests. When ketamine or (2R,6R)-HNK was administered on withdrawal day 29, both treatments alleviated deficits in the tail suspension test but lacked effects in other behaviors.
These findings demonstrate the therapeutic potential of (2R,6R)-HNK and ketamine in alleviating affective symptoms of oxycodone withdrawal. In subjects with opioid use disorder (OUD), affective symptoms persist long after opioid cessation and contribute to poor treatment outcomes. (2R,6R)-Hydroxynorketamine (HNK), a ketamine metabolite, has emerged as promising rapid-acting and long-lasting antidepressants, but its potential to reduce affective symptoms during protracted oxycodone withdrawal and the mechanism of action remain unclear.RATIONALEIn subjects with opioid use disorder (OUD), affective symptoms persist long after opioid cessation and contribute to poor treatment outcomes. (2R,6R)-Hydroxynorketamine (HNK), a ketamine metabolite, has emerged as promising rapid-acting and long-lasting antidepressants, but its potential to reduce affective symptoms during protracted oxycodone withdrawal and the mechanism of action remain unclear.The objective of this study is to investigate the effects of (2R,6R)-HNK and ketamine on affective-like behaviors during oxycodone withdrawal and evaluate the underlying mechanism.OBJECTIVEThe objective of this study is to investigate the effects of (2R,6R)-HNK and ketamine on affective-like behaviors during oxycodone withdrawal and evaluate the underlying mechanism.Male and female C57BL/6 N mice were injected with saline or escalating dose of oxycodone for eight consecutive days followed by 30 days of protracted withdrawal. On withdrawal day 1 or 29, mice were treated with saline, (2R,6R)-HNK (10 mg/kg), s.c.), or ketamine (10 mg/kg, s.c.) prior to the social interaction, sucrose preference, or tail suspension test on withdrawal day 30. Additionally, to determine if AMPA receptor signaling was necessary for the treatment effect, NBQX (AMPA receptor antagonist) was administered prior to (2R,6R)-HNK or ketamine in a different cohort of mice.METHODSMale and female C57BL/6 N mice were injected with saline or escalating dose of oxycodone for eight consecutive days followed by 30 days of protracted withdrawal. On withdrawal day 1 or 29, mice were treated with saline, (2R,6R)-HNK (10 mg/kg), s.c.), or ketamine (10 mg/kg, s.c.) prior to the social interaction, sucrose preference, or tail suspension test on withdrawal day 30. Additionally, to determine if AMPA receptor signaling was necessary for the treatment effect, NBQX (AMPA receptor antagonist) was administered prior to (2R,6R)-HNK or ketamine in a different cohort of mice.Both (2R,6R)-HNK and ketamine reversed oxycodone-induced deficits to a similar degree in all behavior tests when administered on withdrawal day 1, and pre-treatment with NBQX attenuated this effect in the tail suspension test but not the social interaction or sucrose preference tests. When ketamine or (2R,6R)-HNK was administered on withdrawal day 29, both treatments alleviated deficits in the tail suspension test but lacked effects in other behaviors.RESULTSBoth (2R,6R)-HNK and ketamine reversed oxycodone-induced deficits to a similar degree in all behavior tests when administered on withdrawal day 1, and pre-treatment with NBQX attenuated this effect in the tail suspension test but not the social interaction or sucrose preference tests. When ketamine or (2R,6R)-HNK was administered on withdrawal day 29, both treatments alleviated deficits in the tail suspension test but lacked effects in other behaviors.These findings demonstrate the therapeutic potential of (2R,6R)-HNK and ketamine in alleviating affective symptoms of oxycodone withdrawal.CONCLUSIONSThese findings demonstrate the therapeutic potential of (2R,6R)-HNK and ketamine in alleviating affective symptoms of oxycodone withdrawal. |
| Author | Lehane, Michael J. Sartor, Gregory C. |
| Author_xml | – sequence: 1 givenname: Michael J. surname: Lehane fullname: Lehane, Michael J. – sequence: 2 givenname: Gregory C. orcidid: 0000-0002-2228-1830 surname: Sartor fullname: Sartor, Gregory C. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/41045335$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kdtOwzAMhiM0BOPwAlygXA6JgHNo2l6iiZOEhITgOkoaVyt0DSTdxl6A56ZsgG8s6_9s2f4PyKgLHRJywuGCA-SXCUBwyUBkDHQpFNM7ZMyVFExALkZkDCAlkzwr9slBSq8whCrUHtlXHFQmZTYmX88zpFjXWPWJhpq2YcV8SEjfsLfzpkNqO08n4ulcP52xu7WP4XPdhfgvh47aTXuzROpwZpdNiInalELV2B49XTX9jL7H0Edb_dTDgCr44ZSN4qNd2faI7Na2TXj8mw_Jy8318_SOPTze3k-vHlglMt0zVTvtscyl84oL7qUqtYOaWyiELZUuKudzJcDxshbWoQNe8MI7rjgWoIU8JJPt3GGfjwWm3sybVGHb2g7DIhkpsnz4TS7lgJ7-ogs3R2_eYzO3cW3-fjcAYgtUMaQUsf5HOJgfg8zWIDMYZDYGGS2_ASWQhAs |
| Cites_doi | 10.1155/2016/7620860 10.1016/j.bbr.2014.05.065 10.7554/eLife.86022 10.1038/s41380-022-01673-w 10.1101/2023.12.07.570550 10.1177/2045125320916657 10.1097/ALN.0000000000000285 10.1016/j.nbd.2023.106279 10.1016/j.neuropharm.2022.109308 10.1016/j.ynstr.2022.100503 10.1016/j.pbb.2020.172927 10.1016/j.bja.2018.03.011 10.1038/mp.2017.239 10.1111/j.1521-0391.2011.00186.x 10.1002/da.22490 10.1016/j.biopsych.2010.08.021 10.1016/j.pneurobio.2015.12.001 10.1016/j.bbr.2011.05.035 10.1503/jpn.160175 10.1073/pnas.1819540116 10.1016/j.biopsych.2007.05.028 10.3389/fnbeh.2020.00075 10.1002/cpt.3391 10.1126/science.1190287 10.1124/molpharm.124.000947 10.1016/S0022-3565(25)31050-5 10.1016/j.ejphar.2016.07.006 10.1038/s41386-020-00927-x 10.1177/2167702619855659 10.1172/JCI130808 10.1016/j.biopsych.2024.09.008 10.1038/mp.2016.39 10.1016/j.neuropharm.2018.01.017 10.1038/s41386-018-0084-y 10.1016/j.ejphar.2025.177604 10.1523/JNEUROSCI.2875-12.2016 10.1124/pr.117.015198 10.1038/s41386-018-0102-0 10.1038/s41386-022-01422-1 10.1111/ejn.14580 10.1016/j.biopsych.2017.10.020 10.1016/j.ejphar.2012.11.023 10.1080/15504263.2021.1979349 10.1111/bph.70018 10.3389/fpsyt.2023.1183740 10.3390/brainsci13101445 10.1016/j.brainresbull.2016.05.016 10.1038/nature17998 10.1371/journal.pone.0301848 10.1007/s11064-004-6884-y 10.7759/cureus.15309 10.1016/j.drugalcdep.2023.110987 10.1016/j.neuron.2022.09.024 10.1097/FBP.0b013e3282fe88a0 10.1038/s41386-019-0443-3 10.1016/j.jphs.2024.01.008 10.1016/j.neuropharm.2022.109276 10.1073/pnas.1816071116 10.1101/2024.07.29.605610 |
| ContentType | Journal Article |
| Copyright | 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| Copyright_xml | – notice: 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1007/s00213-025-06924-6 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-2072 |
| ExternalDocumentID | 41045335 10_1007_s00213_025_06924_6 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Connecticut Institute for the Brain and Cognitive Sciences grantid: Connecticut Institute for the Brain and Cognitive Sciences |
| GroupedDBID | 40D 40E 95. 95~ AAYXX ABMNI AGWIL ALMA_UNASSIGNED_HOLDINGS CITATION RHV SBY SOJ ~EX --- .86 .VR 04C 06C 06D 0R~ 0VY 123 199 1N0 203 29P 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 36B 4.4 406 408 409 5RE 5VS 67N 67Z 6NX 78A 7RV 8TC 8UJ 95- 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANZL AAPKM AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYZH ABAKF ABBBX ABBRH ABBXA ABDBE ABDBF ABDZT ABECU ABFSG ABFTV ABHLI ABHQN ABIPD ABIVO ABJNI ABJOX ABKCH ABKTR ABMQK ABNWP ABPLI ABQBU ABRTQ ABSXP ABTEG ABTHY ABTKH ABTMW ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACNCT ACOKC ACOMO ACPIV ACPRK ACSTC ACZOJ ADBBV ADHHG ADHIR ADIMF ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEFQL AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AEZWR AFBBN AFDZB AFHIU AFLOW AFOHR AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AIIXL AILAN AITGF AIXLP AJRNO AJZVZ AKMHD ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG ATHPR AVWKF AXYYD AYFIA AZFZN B-. BA0 BENPR BGNMA BMSDO BSONS CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DXH EAP EBLON EBS EIOEI EPAXT ESBYG ESX F5P FEDTE FERAY FFXSO FIGPU FNLPD FRRFC FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ7 GQ8 GXS HF~ HG5 HG6 HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICJ IHE IHR IJ- IKXTQ IMOTQ INH INR IPY ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M4Y MA- N9A NAPCQ NB0 NPM NPVJJ NQJWS NU0 O93 O9G O9I O9J OAM P19 P2P PF- PT4 PT5 QOK QOR QOS R89 R9I ROL RPX RRX RSV S16 S1Z S27 S3A S3B SAP SBL SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SPISZ SRMVM SSLCW SSXJD SZN T13 TN5 TSG TSK TSV TUC TUS U2A U9L UG4 UOJIU UTJUX VC2 W23 W48 WH7 WIP WJK WK8 YLTOR Z45 ZMTXR ZOVNA 7X8 ABUFD |
| ID | FETCH-LOGICAL-c256t-4fb6de973bd4121d3496b0f1a082a9468cbd7420b19f2abeb01818db141e80623 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001586440000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0033-3158 1432-2072 |
| IngestDate | Tue Oct 07 05:49:19 EDT 2025 Sun Oct 05 01:50:55 EDT 2025 Thu Oct 09 00:19:31 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | AMPA receptor Affective symptoms Ketamine Oxycodone Protracted withdrawal Opioid use disorder (2R,6R)-Hydroxynorketamine |
| Language | English |
| License | 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c256t-4fb6de973bd4121d3496b0f1a082a9468cbd7420b19f2abeb01818db141e80623 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-2228-1830 |
| PMID | 41045335 |
| PQID | 3257104733 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3257104733 pubmed_primary_41045335 crossref_primary_10_1007_s00213_025_06924_6 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-10-04 |
| PublicationDateYYYYMMDD | 2025-10-04 |
| PublicationDate_xml | – month: 10 year: 2025 text: 2025-10-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany |
| PublicationTitle | Psychopharmacology |
| PublicationTitleAlternate | Psychopharmacology (Berl) |
| PublicationYear | 2025 |
| References | Y Liu (6924_CR26) 2016; 126 TM Hillhouse (6924_CR17) 2024; 19 BD Kiluk (6924_CR20) 2019; 7 P Zanos (6924_CR57) 2018; 70 E Dakwar (6924_CR8) 2017; 22 TH Pham (6924_CR38) 2018; 84 R Moaddel (6924_CR34) 2013; 698 SM Raja (6924_CR40) 2024; 116 MG Craske (6924_CR7) 2016; 33 IM Bravo (6924_CR4) 2020; 51 D Ji (6924_CR19) 2004; 29 JAJ Becker (6924_CR2) 2021; 46 P Zanos (6924_CR58) 2019; 116 J Bonaventura (6924_CR3) 2022; 27 6924_CR10 6924_CR16 A Onisiforou (6924_CR36) 2025; 97 A Zaytseva (6924_CR59) 2023 A Suzuki (6924_CR43) 2023; 222 R Zafar (6924_CR55) 2023; 14 J-I Yamaguchi (6924_CR52) 2018; 43 H Chalana (6924_CR5) 2016; 2016 RM Enga (6924_CR11) 2016; 789 PE Vlisides (6924_CR48) 2018; 121 RK Paul (6924_CR37) 2014; 121 S Maeng (6924_CR29) 2008; 63 SE Russell (6924_CR42) 2016; 36 SM Thompson (6924_CR44) 2023; 48 J Tkacz (6924_CR45) 2012; 21 Y Chen (6924_CR6) 2023; 186 MB Pomrenze (6924_CR39) 2022; 110 I Ivan Ezquerra-Romano (6924_CR18) 2018; 142 A Yamagishi (6924_CR51) 2024; 154 I Gomes (6924_CR15) 2024; 106 KN Tormohlen (6924_CR46) 2021; 17 I Koutrouli (6924_CR23) 2025; 999 R Machado-Vieira (6924_CR28) 2017; 152 MV Fogaça (6924_CR12) 2024 D Matveychuk (6924_CR30) 2020; 10 LM Riggs (6924_CR41) 2020; 45 H Koike (6924_CR21) 2011; 224 H Zhai (6924_CR60) 2008; 19 A Michael (6924_CR33) 2025; 182 CR Drinkuth (6924_CR9) 2023; 253 EW Lumsden (6924_CR27) 2019; 116 6924_CR32 JG Yost (6924_CR54) 2022; 221 Y Li (6924_CR25) 2022; 21 O Vranjkovic (6924_CR49) 2018; 43 JM Witkin (6924_CR50) 2020; 194 N Yao (6924_CR53) 2018; 23 C Goeldner (6924_CR14) 2011; 69 LR Aleksandrova (6924_CR1) 2017; 42 T Tumenta (6924_CR47) 2021; 13 DM Gerhard (6924_CR13) 2020; 130 H Koike (6924_CR22) 2014; 271 G McKendrick (6924_CR31) 2020; 14 JE Moreton (6924_CR35) 1977; 203 P Zanos (6924_CR56) 2016; 533 N Li (6924_CR24) 2010; 329 |
| References_xml | – volume: 2016 year: 2016 ident: 6924_CR5 publication-title: J Addict doi: 10.1155/2016/7620860 – volume: 271 start-page: 111 year: 2014 ident: 6924_CR22 publication-title: Behav Brain Res doi: 10.1016/j.bbr.2014.05.065 – year: 2023 ident: 6924_CR59 publication-title: Elife doi: 10.7554/eLife.86022 – volume: 27 start-page: 4144 issue: 10 year: 2022 ident: 6924_CR3 publication-title: Mol Psychiatry doi: 10.1038/s41380-022-01673-w – ident: 6924_CR32 doi: 10.1101/2023.12.07.570550 – volume: 10 year: 2020 ident: 6924_CR30 publication-title: Ther Adv Psychopharmacol doi: 10.1177/2045125320916657 – volume: 121 start-page: 149 issue: 1 year: 2014 ident: 6924_CR37 publication-title: Anesthesiology doi: 10.1097/ALN.0000000000000285 – volume: 186 year: 2023 ident: 6924_CR6 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2023.106279 – volume: 222 start-page: 109308 year: 2023 ident: 6924_CR43 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2022.109308 – volume: 21 year: 2022 ident: 6924_CR25 publication-title: Neurobiol Stress doi: 10.1016/j.ynstr.2022.100503 – volume: 194 year: 2020 ident: 6924_CR50 publication-title: Pharmacol Biochem Behav doi: 10.1016/j.pbb.2020.172927 – volume: 121 start-page: 249 issue: 1 year: 2018 ident: 6924_CR48 publication-title: Br J Anaesth doi: 10.1016/j.bja.2018.03.011 – volume: 23 start-page: 2066 issue: 10 year: 2018 ident: 6924_CR53 publication-title: Mol Psychiatry doi: 10.1038/mp.2017.239 – volume: 21 start-page: 55 issue: 1 year: 2012 ident: 6924_CR45 publication-title: Am J Addict doi: 10.1111/j.1521-0391.2011.00186.x – volume: 33 start-page: 927 issue: 10 year: 2016 ident: 6924_CR7 publication-title: Depress Anxiety doi: 10.1002/da.22490 – volume: 69 start-page: 236 issue: 3 year: 2011 ident: 6924_CR14 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2010.08.021 – volume: 152 start-page: 21 year: 2017 ident: 6924_CR28 publication-title: Prog Neurobiol doi: 10.1016/j.pneurobio.2015.12.001 – volume: 224 start-page: 107 issue: 1 year: 2011 ident: 6924_CR21 publication-title: Behav Brain Res doi: 10.1016/j.bbr.2011.05.035 – volume: 42 start-page: 222 issue: 4 year: 2017 ident: 6924_CR1 publication-title: J Psychiatry Neuroscience: JPN doi: 10.1503/jpn.160175 – volume: 116 start-page: 6441 issue: 13 year: 2019 ident: 6924_CR58 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1819540116 – volume: 63 start-page: 349 issue: 4 year: 2008 ident: 6924_CR29 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2007.05.028 – volume: 14 start-page: 75 year: 2020 ident: 6924_CR31 publication-title: Front Behav Neurosci doi: 10.3389/fnbeh.2020.00075 – volume: 116 start-page: 1314 issue: 5 year: 2024 ident: 6924_CR40 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.3391 – volume: 329 start-page: 959 issue: 5994 year: 2010 ident: 6924_CR24 publication-title: Sci (New York N Y) doi: 10.1126/science.1190287 – volume: 106 start-page: 240 issue: 5 year: 2024 ident: 6924_CR15 publication-title: Mol Pharmacol doi: 10.1124/molpharm.124.000947 – volume: 203 start-page: 303 issue: 2 year: 1977 ident: 6924_CR35 publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)31050-5 – volume: 789 start-page: 75 year: 2016 ident: 6924_CR11 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2016.07.006 – volume: 46 start-page: 1373 issue: 7 year: 2021 ident: 6924_CR2 publication-title: Neuropsychopharmacology doi: 10.1038/s41386-020-00927-x – volume: 7 start-page: 1190 issue: 6 year: 2019 ident: 6924_CR20 publication-title: Clin Psychol Science: J Association Psychol Sci doi: 10.1177/2167702619855659 – volume: 130 start-page: 1336 issue: 3 year: 2020 ident: 6924_CR13 publication-title: J Clin Invest doi: 10.1172/JCI130808 – volume: 97 start-page: 563 issue: 6 year: 2025 ident: 6924_CR36 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2024.09.008 – ident: 6924_CR10 – volume: 22 start-page: 76 issue: 1 year: 2017 ident: 6924_CR8 publication-title: Mol Psychiatry doi: 10.1038/mp.2016.39 – volume: 142 start-page: 72 year: 2018 ident: 6924_CR18 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2018.01.017 – volume: 43 start-page: 1900 issue: 9 year: 2018 ident: 6924_CR52 publication-title: Neuropsychopharmacology doi: 10.1038/s41386-018-0084-y – volume: 999 year: 2025 ident: 6924_CR23 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2025.177604 – volume: 36 start-page: 5748 issue: 21 year: 2016 ident: 6924_CR42 publication-title: J Neuroscience: Official J Soc Neurosci doi: 10.1523/JNEUROSCI.2875-12.2016 – volume: 70 start-page: 621 issue: 3 year: 2018 ident: 6924_CR57 publication-title: Pharmacol Rev doi: 10.1124/pr.117.015198 – volume: 43 start-page: 1915 issue: 9 year: 2018 ident: 6924_CR49 publication-title: Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol doi: 10.1038/s41386-018-0102-0 – volume: 48 start-page: 90 issue: 1 year: 2023 ident: 6924_CR44 publication-title: Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol doi: 10.1038/s41386-022-01422-1 – volume: 51 start-page: 742 issue: 3 year: 2020 ident: 6924_CR4 publication-title: Eur J Neurosci doi: 10.1111/ejn.14580 – volume: 84 start-page: e3 issue: 1 year: 2018 ident: 6924_CR38 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2017.10.020 – volume: 698 start-page: 228 issue: 1–3 year: 2013 ident: 6924_CR34 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2012.11.023 – volume: 17 start-page: 296 issue: 4 year: 2021 ident: 6924_CR46 publication-title: J Dual Diagnosis doi: 10.1080/15504263.2021.1979349 – volume: 182 start-page: 3428 issue: 15 year: 2025 ident: 6924_CR33 publication-title: Br J Pharmacol doi: 10.1111/bph.70018 – volume: 14 start-page: 1183740 year: 2023 ident: 6924_CR55 publication-title: Front Psychiatry doi: 10.3389/fpsyt.2023.1183740 – ident: 6924_CR16 doi: 10.3390/brainsci13101445 – volume: 126 start-page: 68 issue: Pt 1 year: 2016 ident: 6924_CR26 publication-title: Brain Res Bull doi: 10.1016/j.brainresbull.2016.05.016 – volume: 533 start-page: 481 issue: 7604 year: 2016 ident: 6924_CR56 publication-title: Nature doi: 10.1038/nature17998 – volume: 19 start-page: e0301848 issue: 4 year: 2024 ident: 6924_CR17 publication-title: PLoS ONE doi: 10.1371/journal.pone.0301848 – volume: 29 start-page: 2113 issue: 11 year: 2004 ident: 6924_CR19 publication-title: Neurochem Res doi: 10.1007/s11064-004-6884-y – volume: 13 start-page: e15309 issue: 5 year: 2021 ident: 6924_CR47 publication-title: Cureus doi: 10.7759/cureus.15309 – volume: 253 year: 2023 ident: 6924_CR9 publication-title: Drug Alcohol Depend doi: 10.1016/j.drugalcdep.2023.110987 – volume: 110 start-page: 4125 issue: 24 year: 2022 ident: 6924_CR39 publication-title: Neuron doi: 10.1016/j.neuron.2022.09.024 – volume: 19 start-page: 211 issue: 3 year: 2008 ident: 6924_CR60 publication-title: Behav Pharmacol doi: 10.1097/FBP.0b013e3282fe88a0 – volume: 45 start-page: 426 issue: 2 year: 2020 ident: 6924_CR41 publication-title: Neuropsychopharmacology doi: 10.1038/s41386-019-0443-3 – volume: 154 start-page: 203 issue: 3 year: 2024 ident: 6924_CR51 publication-title: J Pharmacol Sci doi: 10.1016/j.jphs.2024.01.008 – volume: 221 year: 2022 ident: 6924_CR54 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2022.109276 – volume: 116 start-page: 5160 issue: 11 year: 2019 ident: 6924_CR27 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1816071116 – year: 2024 ident: 6924_CR12 publication-title: BioRxiv: Preprint Serv Biology doi: 10.1101/2024.07.29.605610 |
| SSID | ssj0000484 ssj0068394 |
| Score | 2.4843202 |
| SecondaryResourceType | online_first |
| Snippet | In subjects with opioid use disorder (OUD), affective symptoms persist long after opioid cessation and contribute to poor treatment outcomes.... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database |
| Title | The effects of low-dose ketamine and (2R,6R)-Hydroxynorketamine on affective behaviors associated with protracted oxycodone withdrawal |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/41045335 https://www.proquest.com/docview/3257104733 |
| WOSCitedRecordID | wos001586440000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-2072 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000484 issn: 0033-3158 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fS-QwEB5UDvHl9Lw7XX-Rg0M8botNm6bJo4jig8riqexbSZoURG2P7arsP-Df7Uzb3eXgfPCxTDMpfOlkksn3BeCn1EIbTjv3ppCBkEWOcVDQRj53RkXahUlDFD5PLy_VcKgHC9B_t4J_2NybRLXGJAglrhYC0tfmsiVr_bmdh11BjMv2QeK03-ovx8QeS1RHl_m_v3-npHfyzGa-OV392Jeuwecur2RH7UD4Agu-XIfli65yvg77g1ajetJn13PKVd1n-2wwV6-efIVXNLPulAerCvZQvQSuqj2792PziL6YKR07iK768upXcDZxdA6mrEYzc1Uy0zTHOMqmKgA1M9048I7R3i8jgYhGKtoxdJDj6hjbksWNzIt5-AY3pyfXx2dBd1lDkGPWNA5EYaXzOo2tEzzijoTobVhwgzmG0UKq3DpchoeW6yIy1ltSClPOcsG9ChHO77BUYk-bRCPXPrZK00siLBTp84RaSasSL1Of9uD3FK_sb6vJkc3UlxsMMsQgazDIZA9-TCHN8NeheogpffVUZzGGK1KqiOMebLRYz_wJNGAmnGx9qK9tWIkIfjpgIHZgaTx68rvwKX8e39WjPVhMh2qvGbVvchbhBQ |
| linkProvider | Springer Nature |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effects+of+low-dose+ketamine+and+%282R%2C6R%29-Hydroxynorketamine+on+affective+behaviors+associated+with+protracted+oxycodone+withdrawal&rft.jtitle=Psychopharmacology&rft.au=Lehane%2C+Michael+J.&rft.au=Sartor%2C+Gregory+C.&rft.date=2025-10-04&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007%2Fs00213-025-06924-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00213_025_06924_6 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon |